This review encapsulates significant developments in molecularly targeted agents and immune checkpoint inhibitors, emphasising their clinical efficacy, resistance mechanisms, and innovative therapeutic combinations, and reviews pivotal clinical trials and newly filed patents.
K. C. Geervani, R. Maddileti, Kalpi Sania Kausar et al.· Current Drug Discovery Techn...· 0 citations
Lung cancer is the leading cause of cancer-related deaths worldwide. Over the past decade, immunotherapy, represented by immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1/programmed cell death protein ligand-1 (PD-1/PD-L1) or cytotoxic T lymphocyte associated antigen-4 (CTLA-4), has revoluti...
Jing-Yi Li, Chan Tong, Yong-Chang Chen et al.· Chinese Medical Journal - Pu...· 0 citations
Recent advances in NSCLC with established alterations are summarized, including EGFR, ALK, ROS1, KRAS, BRAF, RET, HER2, MET, and NTRK, and emerging targets are discussed, and emerging targets, such as NRG1 fusions, MTAP loss, and SMARCA4 deficiency are discussed.
L. Hendriks, Jessica J. Lin, D. S. Tan et al.· The Lancet Respiratory Medic...· 2 citations
The role of EGFRvIII in driving aggressive tumor growth is discussed and how effective targeting of EGFRvIII, and overcoming resistance mutations will be crucial to improve EGFR- and EGFRvIII-based therapies are highlighted.
U. Krishnaja, N. J, Maitheli Sarkar et al.· Immunotherapy· 0 citations
Research directions to make ovarian cancer more susceptible to immunotherapy are moving from empiric treatment to more biologically informed, multimodal approaches aimed at overcoming immune suppression, enhancing antitumor immunity, and personalizing treatment for patients with ovarian cancer.
A. Veneziani, Laura Venegas, A. Oza· Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.